Analyzing Predictive Oncology (NASDAQ:AGPU) and Longevity Health (NASDAQ:XAGE)

Longevity Health (NASDAQ:XAGE) and Predictive Oncology (NASDAQ:AGPU) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Valuation & Earnings

This table compares Longevity Health and Predictive Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05 million	0.53	-$10.37 million	($3.91)	-0.08
Predictive Oncology	$1.62 million	4.73	-$12.66 million	($13.50)	-0.17

Longevity Health has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Longevity Health has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Longevity Health and Predictive Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0	0	0	0	0.00
Predictive Oncology	1	0	0	0	1.00

Institutional & Insider Ownership

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Longevity Health and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Predictive Oncology	-5,065.23%	N/A	-235.55%

Summary

Longevity Health beats Predictive Oncology on 6 of the 11 factors compared between the two stocks.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

About Predictive Oncology

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.